Lyell(US:LYEL) Globenewswire·2026-03-12 20:05Core Insights - Lyell Immunopharma is advancing its pipeline of next-generation CAR T-cell therapies, with significant clinical trials underway for its product candidates, including ronde-cel and LYL273 [1][3][4] Financial Performance - For the fourth quarter of 2025, Lyell reported a net loss of $140.7 million, compared to a net loss of $191.9 million in the same period of 2024. The total net loss for the year was $274.4 million, down from $343.0 million in 2024 [7][12] - Research and development expenses for Q4 2025 were $52.2 million, an increase from $48.7 million in Q4 2024. General and administrative expenses decreased to $10.6 million from $14.5 million in the same period [8][11] - As of December 31, 2025, cash, cash equivalents, and marketable securities totaled approximately $247.2 million, down from $383.5 million at the end of 2024 [12][19] Clinical Developments - Lyell has initiated patient dosing in the Phase 3 head-to-head trial (PiNACLE-H2H) comparing ronde-cel to other CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma [1][5][9] - The ongoing Phase 1 trial for LYL273 has treated seven patients with metastatic colorectal cancer without dose-limiting toxicity, demonstrating promising clinical activity [1][10] Product Highlights - Ronde-cel is designed to target B cells expressing either CD19 or CD20, aiming to improve response rates compared to existing therapies. It has received RMAT and Fast Track designations from the FDA [4][6] - LYL273, an enhanced GCC-targeted CAR T-cell product candidate, has shown a 67% best overall response rate in its Phase 1 trial for refractory metastatic colorectal cancer [10][6] Recent Business Developments - The company closed a second tranche of $50 million from its equity private placement, following the achievement of a clinical milestone in the PiNACLE trial [2][5] - Smital Shah has been appointed as Chief Financial and Business Officer, effective March 2026 [2][5]